The Conjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Conjunctivitis. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Conjunctivitis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Conjunctivitis and features dormant and discontinued products.

GlobalData tracks 59 drugs in development for Conjunctivitis by 51 companies/universities/institutes. The top development phase for Conjunctivitis is preclinical with 20 drugs in that stage. The Conjunctivitis pipeline has 59 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Conjunctivitis pipeline products market are: Inmunotek, IACTA Pharmaceuticals and Okogen.

The key targets in the Conjunctivitis pipeline products market include Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC, Histamine H1 Receptor (HRH1), and DNA Topoisomerase IV (EC

The key mechanisms of action in the Conjunctivitis pipeline product include Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC Inhibitor with four drugs in Phase II. The Conjunctivitis pipeline products include 11 routes of administration with the top ROA being Ophthalmic and 12 key molecule types in the Conjunctivitis pipeline products market including Small Molecule, and Allergenics (Allergen).

Conjunctivitis overview

Conjunctivitis, commonly known as “pink eye”, refers to inflammation of the conjunctiva, the thin, transparent layer covering the white part of the eye and the inner surface of the eyelids. This condition can be caused by various factors, including infections, allergies, or irritants. Viral conjunctivitis is typically caused by viruses associated with the common cold; it is highly contagious and often spreads through coughing, sneezing, or direct contact with infected eye secretions. It causes redness, watery eyes, and sometimes a gritty feeling. Bacterial conjunctivitis can lead to redness, swelling, a sticky discharge, and crusty eyelids, especially after sleep. It’s also contagious and can spread through direct contact. Allergic conjunctivitis is triggered by allergens such as pollen, dust, or pet dander, and can result in red, itchy, and watery eyes, and is not contagious. Irritant conjunctivitis is caused by irritants such as smoke, chemicals, or foreign objects entering the eye, leading to redness, watering, and discomfort, and is also not contagious.

For a complete picture of Conjunctivitis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.